HLVX - HilleVax Corp Year-over-year net earnings per share growth for the last 12 months

Brandmark of HilleVax, Inc. (HLVX)

HilleVax, Inc. (HLVX) management is dynamically and effectively optimizing the budget following a strategic shift, as clearly demonstrated by the quarterly earnings per share growth chart. The developer's high standing within the scientific community complements this profile, yet setbacks with norovirus deprive the company of pricing power. Currently, the parameter value reaches 86.50, capturing the business's current financial trend.

hillevax.com (HLVX) Year-over-year net earnings per share change for the last twelve months: for the period 06/21/2023 - 09/27/2025

Summary analytical data breakdowns for hillevax.com (HLVX)

- market value and analyst target forecast:
- market capitalization statistics:
Fundamental valuation:HilleVax, Inc.
Flagship merchandise of HilleVax, Inc.

This indicator measures the dynamics of net earnings per share, reflecting the impact of tax adjustments and government payments on the final return on equity. By analyzing the quarterly growth in earnings per share, an investor can assess how effectively HilleVax, Inc. (HLVX) optimizes costs for complex pharmaceutical transportation and cold chain maintenance to preserve the biological activity of vaccines.

Direct competitors

Gilead Sciences Inc (GILD) - Year-over-year earnings per share growth for the last twelve months|Cidara - Year-over-year earnings per one share growth for the last 12 months|Year-over-year net earnings per share growth for the last 12 months NVAX|Quarterly EPS earnings growth curevac.com|Year-over-year earnings per share growth for the last twelve months Valneva Corp (VALN)|Year-over-year earnings per share growth for the last twelve months VIR (Vir Biotechnology)|Year-over-year earnings per share growth for the last twelve months TPOXX SIGA|EBS - Year-over-year net earnings per share growth for the last 12 months|AVIR: Year-over-year net earnings per share growth for the last 12 months|IVVD (Invivyd Inc) - Year-over-year earnings per share growth for the last 12 months|ENTA: Quarterly EPS earnings growth|INO (Inovio) - Year-over-year earnings per share growth for the last twelve months|KLRS (Kalaris Therapeutics Inc.) - Quarterly EPS earnings growth|Year-over-year earnings per share growth for the last 12 months DYAI (Dyadic International)|Year-over-year net earnings per share growth for the last 12 months NNVC (NanoViricides)|TLPH (Talphera, Inc.) - Year-over-year earnings per one share growth for the last 12 months|Year-over-year earnings per share growth for the last twelve months Cocrystal Pharma Inc COCP|Year-over-year earnings per one share growth for the last 12 months TRAW|Dogwood Therapeutics Inc. - Quarterly EPS earnings growth|Earnings per share growth in annualized terms for the last twelve months Qualigen Corp|ALVR (AlloVir Bio) - Year-over-year net earnings per share growth for the last 12 months|Year-over-year net earnings per share growth for the last 12 months VBI Vaccines, Inc.|VIRI (virios.com) - Quarterly EPS earnings growth|Year-over-year earnings per share growth for the last 12 months VXRT (Vaxart, Inc.)